R ELAXIN, a 6-kDa protein, is classically regarded as a reproductive hormone in a number of mammalian species, with many important implications for the regulation of pregnancy, including modulation of uterine activity and tissue remodeling (1) . In addition to its effects on female reproductive tissues, relaxin is also produced in the male prostate, released into seminal fluid (2, 3) , and may enhance sperm motility (1) . Moreover, relaxin elicits remarkable pleiotropic characteristics in diverse nonreproductive systems with potential physiological and clinical significance that include decreasing fibrosis (4-7), inhibition of histamine release (8) , stimulation of angiogenesis (9) , modulation of blood pressure (10) , enhancement of neuropeptide release (1), regulation of heart rate (11) , and association with congestive heart failure (12) .
Despite the existence of compelling evidence for important roles of relaxin in physiological conditions, until recently little was known about the intracellular signaling pathways initiated by relaxin. Many earlier studies showed that relaxin increased cAMP and activated protein kinase A (PKA) in several cell types and tissues, similar to classical G protein-coupled receptor (GPCR) activation of G s (1, (13) (14) (15) (16) . In contrast, relaxin induced tyrosine phosphorylation of an approximately 220-kDa protein in human uterine fibroblasts (16) (17) (18) (19) , potentially implicating a receptor tyrosine kinase as a relaxin target. Likewise, Bartsch et al. (20) reported that tyrphostins (tyrosine kinase inhibitors) inhibited relaxin-stimulated cAMP response. Zhang et al. (21) recently demonstrated that relaxin activates the MAPK pathway in human endometrial and THP-1 monocytic cells. Finally, relaxin activates the nitric oxide (NO) pathway and increases intracellular cGMP levels in human vascular smooth muscle and breast cancer cells (22, 23) .
Recently, LGR7 and LGR8, formerly orphan GPCRs, were characterized as receptors for relaxin (24) . These receptors stimulated cAMP production when overexpressed in HEK293 cells.
LGR8, but not LGR7, is also a receptor for the relaxin-like factor INSL3 (25) and again gives rise to increased cAMP upon stimulation.
Previous studies have addressed the fact that GPCR agonists can activate phosphoinositide 3-kinase (PI3K), particularly receptors that couple to G i and G q (26, 27) . More recently, a G s -coupled receptor has also been shown to activate PI3K (28) . PI3Ks are lipid kinases that phosphorylate the 3Ј-OH group of the inositol ring in membrane phospholipids to generate intracellular second messengers (reviewed in Refs. [29] [30] [31] . The preferred inositol-containing substrate in intact cells is phosphatidylinositol 4,5-bisphosphate which is converted to phosphatidylinositol 3,4,5-triphosphate. PI3Ks play important roles in gene tran-scription, cytoskeletal remodeling, mitogenic signaling, and metabolic control. The downstream events initiated by PI3Ks are reminiscent of some of the pleiotropic effects of relaxin, many of which are not easily explained by a simple increase in cAMP. We were thus prompted to examine PI3K involvement in relaxinmediated signaling pathways.
In this study, we employed a human monocytic cell line THP-1, which has a robust cAMP response upon relaxin stimulation, as a model system to further investigate the signaling mechanisms initiated by relaxin. Our results indicate relaxin receptors LGR7 and LGR8 are expressed in THP-1 cells. We show that relaxin-stimulated cAMP accumulation is biphasic and demonstrate that PI3K activity is required for the production of the second wave of cAMP by relaxin both in vivo and in vitro.
RESULTS
Using RT-PCR, we show that THP-1 cells express mRNA encoding the relaxin receptors LGR7 and LGR8 (Fig. 1) . The human myometrial cell line PHM1-41 has been used extensively to examine relaxin-mediated responses and also expressed LGR7. A substantially weaker signal was consistently detected with LGR8 in this cell line (Fig. 1) .
Relaxin Increases cAMP with a Biphasic Time Course
THP-1 cells have been used successfully in a number of laboratories to study relaxin-mediated responses because of their large increases in cAMP accumulation upon treatment with relaxin as compared with other cells and tissues (16, 32, 33) . We also observed a robust 8-fold stimulation of cAMP accumulation by relaxin in THP-1 cells that was highly synergistic with low levels of forskolin ( Fig. 2A) . In these experiments, forskolin concentrations were chosen that generate only a 2-fold increase in cAMP to enhance the synergistic effect. A similar synergy of relaxin with forskolin was described earlier for THP-1 and rat myometrial cells using human and porcine relaxin, respectively (14, 16) .
The time course for cAMP accumulation in THP-1 cells was biphasic with an early peak occurring at approximately 1 min and a second wave of cAMP at 10-20 min (Fig. 2B) . The time course changed slightly in these cells with increasing passage number; however, we consistently observed a biphasic pattern using acetylated EIA detection methods for cAMP both in the presence and absence of phosphodiesterase (PDE) inhibitors. Similar time courses have also been measured using [ 3 H]adenine incorporation methods (data not shown).
PI3K Inhibitors Partially Block Relaxin Stimulation
The cAMP time course is consistent with two potential pathways for relaxin action. Previous reports have suggested that stimulation of cAMP by relaxin is sensitive to tyrosine kinase inhibitors (20, 34) . We found that inhibitors of PI3K also inhibited relaxin-stimulated cAMP accumulation. The specific PI3K inhibitor (LY294002) partially blocked relaxin-mediated increases in cAMP in THP-1 cells, giving rise to a 47 Ϯ 9% inhibition of relaxin stimulation in six separate experiments (Fig. 3A) . However, pretreatment with LY294002 had no effect on the stimulation of adenylyl cyclase (AC) by forskolin or isoproterenol (a ␤-adrenergic agonist) (Fig. 3A) . cAMP accumulation was measured after 20 min of relaxin stimulation in these initial experiments to measure the second wave of cAMP production. The partial block of relaxin-stimulated cAMP accumulation was also observed with the more general PI3K inhibitor (wortmannin) (Fig. 3B ). LY294002 exhibited a dose-dependent inhibition with an IC 50 of 8 M (Fig. 3C ), similar to the IC 50 for inhibition of the purified PI3K enzyme by LY294002 (1.4 M) (35) . Both LY294002 (Fig. 3D ) and wortmannin (data not shown) preferentially inhibited the second wave of cAMP accumulation. The first peak of cAMP production was inhibited by approximately 30%, whereas the second wave of cAMP production was inhibited by more than 70% by LY294002.
We postulate that the partial block elicited by the PI3K inhibitors is a consequence of the stimulation of multiple pathways by relaxin, only one of which is sensitive to these inhibitors. Activation of G␣ s and its subsequent activation of AC occurs very rapidly (32) and is consistent with the peak at 1-2 min. This mechanism is insensitive to the effects of PI3K inhibitors as demonstrated for stimulation of cAMP production by the ␤-adrenergic receptor (Fig. 3A) . However, the second wave of cAMP is not consistent with the effects observed with most G s -coupled receptors (32, 36) . The second pathway leading to an increase in cAMP requires PI3K activity. Additional evidence for these two mechanisms was derived from in vitro studies of relaxin with purified plasma membrane preparations from THP-1 cells.
Reconstitution of Relaxin Signaling Requires Membrane and Cytosolic Components
Relaxin has previously been shown to generate a 25% and 40% increase in AC activity in isolated plasma membrane preparations from nonpregnant rat myometrium and THP-1 cells, respectively (20, 37) . Our membrane preparations showed a 1.5-fold stimulation of cAMP production by relaxin that was relatively insensitive to the PI3K inhibitor, LY294002 (Fig. 4A ). PI3K is mainly cytosolic, and one potential mechanism of activation is translocation to the membrane by protein-protein interactions (29) . The presence of PI3K was therefore not expected in our membrane preparations. The increase in cAMP in purified plasma membranes was most likely due to an activation of G␣ s by the LGR7 and/or LGR8 relaxin receptor. However, if unstimulated cytosol derived from THP-1 cells was added back to the membrane preparations, the relaxin-mediated stimulation of cAMP production was enhanced and LY294002 sensitivity was restored (Fig.  4A) . In this system, inhibitors of PI3K only partially blocked the increase in cAMP production by relaxin as was observed in whole cells (Fig. 3) . In contrast, PI3K inhibitors have no significant effect on isoproterenolstimulated cAMP production in membranes alone or in membranes reconstituted with cytosol (Fig. 4B) . Hence LGR7 and/or LGR8 receptors mediate a mechanism distinct from that of ␤-adrenergic receptors. The IC 50 for inhibition by LY294002 in the reconstitution system upon relaxin stimulation was approximately 3 M (Fig. 4C) , similar to that observed in whole cells (Fig. 3C ).
Relaxin Increases PI3K Activity
PI3K activity was required not only for biphasic cAMP accumulation by relaxin; it was also stimulated upon relaxin treatment in THP-1 cells. We assessed PI3K activity using an in vitro lipid kinase assay. Briefly, cells (passage nos. 14-25) were stimulated with relaxin for 5 min, lysed, and subjected to immunoprecipitation using an antibody against phosphotyrosine. The immunoprecipitates were then assayed for lipid kinase activity. Using phosphatidylinositol as the substrate, relaxin stimulated a significant (P Ͻ 0.05) increase in the lipid kinase activity of PI3K (1.45 Ϯ 0.03 fold; n ϭ 6) (Fig. 5) . Pretreatment with wortmannin for 30 min nearly eliminated the relaxin-stimulated increase in PI3K activity. Basal activity of THP-1 cells was unaffected by wortmannin. In addition, we also observed a 2.1 Ϯ 0.6-fold increase in PI3K activity upon longer stimulation with relaxin (20 min; passage no. 40) (data not shown).
Relaxin-Stimulated Increase in cAMP Is Not Directly Mediated by a PDE
Bartsch et al. (20) originally proposed that relaxin stimulated a tyrosine kinase receptor, which in turn led to the inhibition of a PDE, possibly PDE8, thus resulting in the elevation of cAMP. We have used two PDE inhibitors to determine whether the PI3K-dependent pathway stimulated by relaxin requires inhibition of a PDE. If this is the case, inhibition of PDE should attenuate the ability of relaxin to increase cAMP. Isobutylmethylxanthine (IBMX) is a general PDE inhibitor for most classes of PDEs but not PDE8 (38, 39) . Dipyridamole inhibits the cGMPdependent PDEs and PDE8A and B (IC 50 ϭ 5-40 M) (38, 39) . The inclusion of the PDE inhibitor IBMX did not alter the biphasic nature of the cAMP time course upon relaxin stimulation in THP-1 cells (Fig.  2B) . Although IBMX significantly increased basal and relaxin-stimulated cAMP as expected, the inhi- bition of PDE activity is not the mechanism of the PI3K-required second wave of cAMP accumulation. Relaxin-mediated stimulation of cAMP remained sensitive to LY294002 (30-50% inhibition) in the presence of dipyridamole and a wide range of IBMX concentrations (Fig. 6 ). In addition, if relaxin increased cAMP solely by decreasing PDE8 activity, an inhibitor of PDE8 should also increase cAMP. No elevation of cAMP by dipyridamole was observed; rather we generally observed an inhibition of both basal and relaxin-mediated stimulation. This decrease in cAMP may reflect the nonspecific nature of dipyridamole, which also has effects on nucleotide transport and metabolism (40, 41) .
On the basis of these data, we suggest a working model for relaxin-mediated cAMP accumulation in THP-1 cells (Fig. 7) . Specific aspects of this model and potential downstream signaling components are discussed below.
DISCUSSION
The molecular mechanisms by which relaxin elicits downstream effects, including how it elevates cAMP, have been unclear. The recent identification of LGR7 and LGR8 as G protein-coupled relaxin receptors (24) points to a direct mechanism for cAMP production via G␣ s stimulation of AC. However, a number of studies have implicated tyrosine kinases in the action of relaxin. Relaxin increased tyrosine phosphorylation of unidentified proteins in human uterine fibroblasts and atrial myocytes (42) . Tyrosine kinase inhibitors attenuated the ability of relaxin to increase cAMP in THP-1 cells (20) , human endometrial stroma cells (20) , and human myometrium (34) and inhibited relaxin-stimulated nitrite accumulation in vascular smooth muscle cells (23) . Taken together, these data suggest that relaxin may activate multiple pathways by a common receptor.
Fig. 4. PI3K Inhibitor LY294002 Inhibits Relaxin-Mediated Increases in cAMP in Vitro
Purified plasma membranes from THP-1 cells (60 g) were pretreated with 50 M IBMX in the presence or absence of 100 M LY294002 for 20 min. Adenylyl cyclase activity was measured upon stimulation with vehicle, 1 g/ml of relaxin (A), or 100 nM isoproterenol (Iso) (B) for 20 min at 30 C. Where indicated, cytosol (0.3 mg/ml final) was added to plasma membranes before pretreatment with inhibitors and then assayed as before. Significant differences ( ‫ء‬ , P Ͻ 0.05) within a group are designated (t test). C, Dose-dependent inhibition by LY294002 of reconstituted membranes and cytosol was measured as described in panel A. Data for panels A and C are expressed as the mean Ϯ SE and are representative of two different experiments. Data presented in panel B are the average of two experiments each performed in duplicate.
The mRNA for LGR7 and LGR8 is present in THP-1 cells. The time course of cAMP stimulation by relaxin is biphasic in these cells with an early peak detected at 1 min and a later wave of cAMP accumulation at 10-20 min. This same biphasic time course was observed in many of the initial relaxin studies in uterine strips and myometrial cells, often as a predominantly delayed signal at 15-20 min with a slight but reproducible early peak (13, 14) . This is in stark contrast to time courses of cAMP accumulation observed with agonists of the ␤-adrenergic receptor and other G s -coupled receptors in myometrial and S49 lymphoma cells (14, 32) . For example, isoproterenol produces a sharp increase in cAMP production between 1 and 5 min in a large number of cell types, including THP-1 cells (data not shown). cAMP levels then either decrease or plateau, depending on the presence and concentration of PDE inhibitors.
The biphasic cAMP time course suggests that at least two pathways may be acting to increase cAMP accumulation upon stimulation with relaxin: a G␣ s membrane delimited pathway, and a second somewhat delayed pathway. Inhibitors of PI3K activity block cAMP accumulation but only with a maximum inhibition of approximately 50%. No inhibitory effect was observed upon activation with a ␤-adrenergic receptor agonist or a direct adenylyl cyclase activator, forskolin. More importantly, the inhibition was dose-dependent and was more prominent for the second wave of cAMP production.
To further explore the role of PI3K, we have performed reconstitution experiments with cytosolic and purified plasma membrane preparations from THP-1 cells. Relaxin stimulation increased cAMP production 1.5-fold in purified plasma membrane preparations that were insensitive to an inhibitor of PI3K, consistent with a direct activation of AC by G␣ s . However, reconstitution of plasma membranes with cytosol further increased stimulation by relaxin and resulted in a dose-dependent partial inhibition by LY294002, consistent with a second pathway containing at least one cytosolic component. Stimulation of cAMP production by isoproterenol was unaffected by LY294002 upon reconstitution of membranes with cytosol.
Our model for relaxin stimulation of cAMP is presented in Fig. 7 and involves an activation of PI3K by relaxin. Stimulation of THP-1 cells with relaxin significantly increased PI3K activity. There are several distinct classes of phosphoinositide kinases. p110␥ belongs to class Ib and is the main member of the subfamily that is sensitive to hormones and neurotransmitters interacting with GPCRs (27) . G␤␥ complexes interact directly with p110␥ to activate this enzyme (43) . However, members of the class Ia and class II families may also be regulated by G proteins (via either G␣-or G␤␥-subunits) by other less defined mechanisms (27) . Further studies are required to identify a specific isoform of PI3K involved in this pathway.
Neither the biphasic nature of relaxin stimulation nor the sensitivity to PI3K inhibitors was mediated by PDEs as originally proposed (20) . The fold increase for relaxin stimulation of cAMP and inhibition by LY294002 remained constant over a 20-fold concentration range of cAMP with increasing concentrations of IBMX (Fig. 6) . Dipyridamole, an inhibitor of PDE8, also had no effect on the inhibition by PI3K inhibitors; however, this drug has many side effects. Even in the absence of a good PDE8 inhibitor, we can rule out PDE8 involvement with the following kinetic argument. Due to the low Michaelis-Menten constant (K m ) of PDE8, the enzyme is essentially fully active at low cAMP concentrations, and therefore the amount of cAMP hydrolyzed by PDE8 remains essentially constant over a large range of cAMP. Hence, at higher cAMP concentrations, the fraction of cAMP hydrolyzed by PDE8 is decreased. Any inhibition of PDE8 by relaxin would produce a greater effect at low concen- THP-1 cells (passage nos. 14-25) were starved in 1% dextran-coated charcoal-stripped FBS for 24 h and pretreated with wortmannin (100 nM) or vehicle control [dimethylsulfoxide (DMSO)] for 30 min at 37 C. Cells were then stimulated with 1 g/ml relaxin (R) for 5 min, subjected to centrifugation, and lysed upon addition of lysis buffer. PI3K was immunoprecipitated from cell lysates using a monoclonal antibody directed against phosphotyrosine as described in Materials and Methods. Subsequently, an in vitro lipid kinase assay was performed using phosphatidylinositol (PI) and [␥- 32 P]ATP as substrate. The product, 32 P-labeled phosphatidylinositol 3-phosphate (PIP), was then separated by TLC and visualized and quantitated by autoradiography. Results are expressed as fold activation over control from several independent experiments (n ϭ 3-6), each performed in duplicate or triplicate (upper graph). Significant differences between groups are identical to those obtained from individual experiments (P Ͻ 0.05; ANOVA analysis and Duncan's test) and are designed by different lowercase letters. Shown in the lower panel is a representative autoradiograph of a TLC plate from a single experiment in which the product PIP is visualized.
trations of cAMP; this was not observed in THP-1 cells.
We propose a bifurcated pathway for cAMP generation that involves the activation of both G␣ s and PI3K. There are few examples of stimulation of an effector molecule by two pathways generated from a single G s -coupled receptor. Both types I and II AC can be regulated by direct binding of G␣ s -and G␤␥-subunits, but in the case of type II AC it is unclear whether this occurs in vivo by activation of the same receptor or by activation of both G s -and G i -coupled receptors (44, 45) . L-type Ca 2ϩ channels can also be regulated by G s -coupled receptors via two distinct pathways involving G␣ s activation of PKA and G␤␥ activation of protein kinase C (PKC) (46) . It is also possible that LGR7 and/or LGR8 can activate another heterotrimeric G protein in addition to G s . However, in THP-1 cells, pertussis toxin treatment has no effect on the fold stimulation of cAMP accumulation by relaxin, ruling out effects of G i , G o , or G z (20) . Although relaxin stimulates PKA activation in PHM1-41 cells or rat myometrium, relaxin has never been observed to increase Ca 2ϩ release or stimulate phospholipase C␤, typical of G q -mediated effects (Refs. 47 and 48 and data not shown). Finally, we cannot rule out stimulation of G 12 or G 13 although these G proteins are often associated with cytoskeletal reorganization and focal adhesion assembly not typically observed upon relaxin treatment (49) . Therefore, at present our model includes only activation of G s . Whether relaxin utilizes G␣ s or G␤␥ to activate PI3K remains to be determined.
It is unclear what downstream events lead from PI3K activation to stimulation of AC. It has been suggested that PI3K activity may serve to compartmentalize G s signaling in some cell types (50) . This could be one potential mechanism for enhancement. Alternatively, phosphatidylinositol 3,4,5-triphosphate generated by PI3K may activate downstream components that serve to enhance AC activity. Studies employing relatively specific chemical inhibitors of PI3K and more recent studies using dominant-negative PI3K molecules have identified several downstream enzymes that are activated by PI3K; these enzymes include phosphoinositide-dependent protein kinase, protein kinase B (Akt), p70 ribosomal S6-kinase, protein kinase C⑀ and -(PKC⑀ and PKC), and ERK 1/2 (31, 51, 52) . Relaxin is unable to activate Akt in normal endometrial cells (21) or in THP-1 cells (data not shown). However, relaxin can activate MAPK in THP-1 cells, endometrial cells, and pulmonary and cardiac smooth muscle cells (21) . MAPK activation is often downstream of PI3K activation for a number of G s -, G q -, and G i -coupled receptors (52, 53) . However, it is unclear how increased ERK activation can lead to increased AC activity. One intriguing downstream effector of PI3K is PKC, which is a direct activator of type V AC and displays synergy with both forskolin and G␣ s stimulation of AC (54) . Further studies are required to determine the role of PKC or any other PKC in the regulation of cAMP by relaxin.
Relaxin clearly increases cAMP and activates protein kinase A in a number of tissues and cell lines. However, additional pathways are also activated in response to relaxin, including increased tyrosine phosphorylation, ERK phosphorylation, and NO synthase expression and the subsequent generation of cGMP. It is possible that in addition to cAMP generation, stimulation of PI3K by relaxin is involved in these pathways as well. By stimulation of two distinct signal transduction pathways, relaxin treatment may have pleiotropic downstream effects, many of which may have useful clinical applications. 
MATERIALS AND METHODS

Materials
Cell Culture
The human monocytic cell line THP-1 was cultured at 37 C and 5% CO 2 in RPMI 1640 containing 2 mM L-glutamine, 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. Cells were used at a density of approximately 1 ϫ 10 6 cells/ml. Culture of the immortalized pregnant human myometrial cell line PHM1-41 has been described previously (55) .
Assay for Relaxin-Mediated Increase in cAMP Production
Cultured cells were washed with prewarmed PBS and resuspended with cell suspension media (RPMI 1640 ϩ 50 mM HEPES, pH 7.4) at 37 C. Cells were pretreated with PDE inhibitor (50 M IBMX) for 15 min, and then treated with 0.5 g/ml relaxin for 20 min, except where indicated. Treatments were terminated by addition of 1 N HCl (0.1 N HCl final). Total cAMP (intra-and extracellular) was detected by enzyme immunoassay. Data represent mean Ϯ SE and were analyzed by one-way ANOVA (where indicated) and Duncan's modified multiple range test and t test.
RT-PCR Analysis
Poly(A)
ϩ RNA was isolated from human THP-1 and PHM1-41 cells, and then reverse transcribed and amplified by PCR as previously described (24) . Briefly, 1 ϫ 10 7 cells were harvested by centrifugation at 1500 rpm for 5 min and washed twice with cold PBS and resuspended in lysis buffer provided by Fast Track 2.0 kit (Invitrogen, San Diego, CA). Poly (A) ϩ RNA was isolated with the FastTrack 2.0 kit according to the manufacturer's protocol. For cDNA synthesis, 2 g of Poly(A) ϩ RNA and 2.5 mM oligo (deoxythymidine) were heated to 65 C for 5 min, chilled on ice for 5 min, and centrifuged briefly. The following components were added to the annealed oligo deoxythymidine/template: AMV buffer, 0.2 mM deoxynucleotide triphosphate mix, 1 U/l RNAsin Ribonuclease inhibitor, nuclease-free water, and 1 U/l AMV reverse transcriptase followed by incubation at 42 C for 1.5 h. PCRs were carried out in a final volume of 20 l containing 5 l of cDNA, 125 M deoxynucleotide triphosphate mix, 500 M primers, PCR buffer, and 2.5 U of Taq DNA polymerase. PCR conditions were: 95 C for 90 sec followed by 35 cycles (94 C for 30 sec and 68 C for 3 min) and final extension (72 C for 5 min). PCR products were electrophoresed on a 1.5% agarose gel, stained with 0.5 g/ml ethidium bromide, and visualized under UV light. Primer sets used for amplification of LGR7 and LGR8 were as described (24) , with the exception of the LGR8 forward primer: 5Ј-CACAGAGAGCACAGCA-GAATGGCT.
Preparation and Reconstitution of Plasma Membrane and Cytosol
THP-1 cells were pelleted, washed twice with cold buffer A (137 mM NaCl, 5.36 mM KCl, 1.1 mM KH 2 PO 4 , 1.08 mM Na 2 HPO 4 , final pH 7.2), and resuspended in buffer B (150 mM NaCl, 20 mM HEPES, 1 mM EDTA, and 1 mM benzamidine, final pH 7.4). Cells were disrupted by nitrogen cavitation (pressurized at 500 pounds per square inch for 25 min on ice). Unbroken cells and nuclei were removed by centrifugation (2600 rpm for 5 min). Half of the supernatant was subjected to centrifugation at 21,000 rpm for 30 min at 4 C to obtain the cytosolic fraction. The other half of the supernatant was centrifuged at 25,000 rpm for 35 min at 4 C to isolate plasma membrane by sucrose sedimentation at the 23%/43% interface (56) . To measure adenylyl cyclase activity, plasma membranes (60 g) were pretreated with 50 M IBMX in the presence or absence of LY294002 for 20 min at 30 C. Vehicle or 1 g/ml relaxin was then added and the reaction started upon addition of 100 M ATP and assay buffer components as described previously (57) . Reactions were terminated after 20 min incubation at 30 C by addition of 1 N HCl (0.1 N final). cAMP was detected by enzyme immunoassay and expressed as picomoles/minute/milligram of membrane protein. Reconstitution experiments were performed by addition of cytosol (0.3 mg/ml) to purified plasma membranes and treated as described above.
PI3K Assay
PI3K activity in immune complexes was assayed as described previously (58) . Briefly, THP-1 cells (1 ϫ 10 7 cells per reaction) were starved in phenol red-free RPMI with 1% charcoal-stripped FBS for 24 h and then stimulated with 1 g/ml of relaxin for 20 min at 37 C. Cell lysates were prepared in lysis buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 20 mM tetrasodium pyrophosphate; 10 mM EDTA; 10% glycerol; 1% Triton X-100; 200 mM NaF; 4 mM Na 3 VO 4 ; 1 mM phenylmethylsulfonyl fluoride; 5 g/ml leupeptin), and proteins were immunoprecipitated with a phosphotyrosine antibody. Immunoprecipitates were washed sequentially in buffer A (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100; and 100 M Na 3 VO 4 ), buffer B (100 mM Tris-HCl, pH 7.5; 500 mM LiCl; and 100 M Na 3 VO 4 ), buffer C (10 mM Tris-HCl, pH 7.5; 100 mM NaCl; 1 mM EDTA; and 100 M Na 3 VO 4 ), and then pellets were dissolved in TNE buffer (10 mM Tris-HCl, pH 7.5; 100 mM NaCl; and 1 mM EDTA). Sonicated phosphatidylinositol (20 g) was added to the immunoprecipitates, and the kinase reaction was started by addition of 30 Ci [␥-32 P]ATP. The reaction was performed at room temperature for 20 min and stopped by addition of a chloroform/ methanol mixture, followed by lipid extraction. The phospholipids in the organic phase were recovered and spotted onto silica gel thin-layer chromatography (TLC) plate precoated with 1% KOH-oxalate. Migration was performed in CH 3 OH-CHCl 3 -H 2 O-25% NH 4 OH (45:35:7:3). The product (phosphatidylinositol 3-phosphate) was then visualized and quantitated using a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
